The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Exploiting Increased Autophagy In Bronchial Epithelial Cells: A New Therapeutic Approach For Chronic Obstructive Pulmonary Disease (COPD)
Funder
National Health and Medical Research Council
Funding Amount
$724,161.00
Summary
COPD is incurable, a leading cause of death, and new therapies are urgently needed. Autophagy is a cell response to cell stress conditions, however increased autophagy is harmful. We will investigate the association of increased autophagy with COPD and smoking and evaluate therapies that can reduce autophagy, including zinc-related drugs and novel antibiotics that have been modified to lose their anti-bacterial activity.
Management Of Breathlessness. Cognitive Behavioural Therapy For People With Chronic Obstructive Pulmonary Disease (BREVE RCT)
Funder
National Health and Medical Research Council
Funding Amount
$402,875.00
Summary
For people with chronic lung disease, breathlessness is common, distressing and difficult to relieve. Pulmonary rehabilitation programs have been demonstrated to improve exercise capacity and quality of life. This study will determine whether changing the way people think about the sensation of breathlessness while completing pulmonary rehabilitation, further reduces distress/anxiety and health service use and improve exercise capacity, disability related to breathlessness and quality of life.
Revolutionising The Diagnosis And Monitoring Of CF Lung Disease
Funder
National Health and Medical Research Council
Funding Amount
$818,391.00
Summary
Cystic fibrosis (CF) lung disease starts early in childhood and relentlessly progresses, with early death a common outcome. There is currently no method capable of detecting very early disease onset nor directly assessing the effectiveness of putative treatments. This project will apply our globally unique X-ray imaging tools, which are capable of imaging lung function at any point across the entire lung, for the very early detection of CF and assessment of clinically applicable treatments.
Clarifying The Pathogenic Role Of Arousal-hyperventilation In Obstructive And Central Sleep Apnoea: Testing Fundamental Pathophysiological Mechanisms And A Strategic New Treatment
Funder
National Health and Medical Research Council
Funding Amount
$414,717.00
Summary
This project is designed to understand the mechanisms underpinning much more stable breathing during deep sleep in obstructive sleep apnoea (OSA). A newly developed analytical technique will be used to examine breathing effort changes across sleep, and interactions with respiratory-induced awakenings in OSA patients. In addition, a new treatment designed to stabilise breathing will be tested and refined towards a new treatment option for OSA and for central sleep apnoea.
Clinical Outcomes, Safety And Incremental Cost Effectiveness Of Multi-level Airway Surgery In Patients With Moderate-severe Obstructive Sleep Apnea (OSA) Who Have Failed Medical Management
Funder
National Health and Medical Research Council
Funding Amount
$652,794.00
Summary
Obstructive sleep apnoea (OSA) is a serious medical disorder with a high public health cost. OSA can be effectively treated but poor treatment compliance is a major clinical problem. As a consequence many OSA patients remain untreated, with significant implications for their long term health. New effective and safe therapies are needed. We believe that we will demonstrate a relatively straightforward, safe and effective surgical procedure for OSA after primary treatments fail. This will lead to ....Obstructive sleep apnoea (OSA) is a serious medical disorder with a high public health cost. OSA can be effectively treated but poor treatment compliance is a major clinical problem. As a consequence many OSA patients remain untreated, with significant implications for their long term health. New effective and safe therapies are needed. We believe that we will demonstrate a relatively straightforward, safe and effective surgical procedure for OSA after primary treatments fail. This will lead to improved patient outcomes.Read moreRead less
Treating Insomnia Co-morbid With Obstructive Sleep Apnoea: A Randomized Controlled Clinical Effectiveness Trial.
Funder
National Health and Medical Research Council
Funding Amount
$600,869.00
Summary
Obstructive Sleep Apnoea (OSA) is a common but serious sleep disorder. Continuous positive airways pressure (CPAP) therapy can be very effective in treating OSA. We have found that many patients with OSA also suffer from insomnia, and this can make it hard for them to begin CPAP therapy and hard for them to stick to it. This trial will examine the effect of treating insomnia concurrently with CPAP, with the expectation that overall treatment outcomes will improve.
Preclinical Evaluation Of A Novel Allosteric IL-1R Inhibitor (rytvela) For The Prevention Of Perinatal Inflammation-induced Fetal Injury
Funder
National Health and Medical Research Council
Funding Amount
$1,377,827.00
Summary
Interleukin-1 (IL-1) is a potent inflammatory protein involved in many inflammatory disorders, including preterm birth (PTB). Blocking the actions of IL-1 in pregnancies at risk of delivering preterm may protect the fetus from PTB and the long-term harm of exposure to inflammation before birth. Using four different models of antenatal inflammation, we will explore the use of a new IL-1 inhibitor to see if it blocks inflammation ‘in utero’ and improve neonatal health and development.
Preclinical Development Of TLR Signalling Inhibitors For Prevention Of Preterm Labour And Fetal Inflammatory Injury
Funder
National Health and Medical Research Council
Funding Amount
$690,821.00
Summary
Preterm birth affects 8% of Australian births and is a major cause of infant and child health problems. Therapies to prevent or delay prematurity are urgently required. This study will investigate new drugs that suppress the triggers of preterm labour. We will evaluate drug effects in mice and human placental tissue, to demonstrate safety and fetal protection from inflammatory injury that occurs with prematurity. Successful completion of the study is expected to lead to clinical trials in women.
Chronic inflammation underlies common and debilitating diseases and causes pain by unknown mechanisms. There is an urgent need to gain a deeper understanding of the mechanisms of chronic pain, which will allow the development of improved therapies with fewer side-effects. Our research program investigates the mechanisms of pain that are associated with inflammatory bowel disease and irritable bowel syndrome, with the goal of developing more effective and selective therapies.
A New Target For Allergic Inflammation: The Sphingolipid Pathway
Funder
National Health and Medical Research Council
Funding Amount
$588,617.00
Summary
Collectively, allergic diseases contribute immensely to the burden of health care in Australia. Notably, allergic reactions are symptomatic responses to a normally innocuous environmental antigen. Allergic diseases include asthma, hay fever, food allergy, anaphylaxis, insect sting and drug allergy. This project aims to understand the underlying mechanisms associated with allergic reactions such that it may aid in the identification of novel targets for the development of new treatments.